Creative Biolabs has expanded its advanced single-cell multi-omics and RNA sequencing solutions, a move that promises to accelerate biomedical discovery by enabling high-resolution cellular profiling across oncology, immunology, and neuroscience. The upgraded suite addresses the growing demand for single-cell resolution in life science research, where dissecting cellular heterogeneity is critical for identifying rare cell subpopulations, characterizing complex tumor microenvironments, and tracing cell lineage trajectories.
The company now offers robust, high-throughput single-cell RNA sequencing services that deliver high sensitivity and coverage across thousands of individual cells. This capability provides high-resolution transcriptomic insights from diverse fresh biological specimens, supporting critical research pipelines that require detailed cellular analysis.
Addressing a long-standing laboratory challenge, Creative Biolabs has also introduced specialized single-nucleus RNA sequencing (snRNA-seq) capabilities. For tissues where single-cell dissociation is prone to cell damage, dissociation-induced stress responses, or selective loss of fragile cell types—such as human brain, myocardium, or flash-frozen clinical biopsies—the company provides an optimized single-cell nuclei RNA sequencing service. By isolating intact nuclei, this approach bypasses harsh enzymatic dissociation and minimizes dissociation-related artifacts while retaining informative nuclear RNA profiles. This dramatically expands the scope of clinical translational research, allowing scientists to analyze samples that were previously difficult or impossible to process.
Recognizing that cellular identity is orchestrated across multiple regulatory layers, Creative Biolabs goes beyond single-dimensional analysis with its high-throughput single-cell multi-omics service. This integrated platform allows simultaneous interrogation of genomic variations, epigenomic landscapes such as chromatin accessibility, cell surface proteomics via CITE-seq, and transcriptomes within identical single cells. By directly linking epigenetic regulation and genomic alterations to gene expression readouts, the service enables researchers to construct multi-dimensional cellular atlases and uncover novel therapeutic targets with unprecedented biological clarity.
"Understanding biology at single-cell and single-nucleus resolution is no longer a luxury—it is fundamental to precision medicine and biomarker discovery," said a senior scientist at Creative Biolabs. "Our goal is to provide researchers with a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support."
The implications of this expansion are significant for the biomedical research community. As precision medicine advances, the ability to analyze individual cells and nuclei from challenging samples will be essential for discovering new biomarkers and therapeutic targets. Creative Biolabs' enhanced offerings, supported by advanced microfluidics technologies, stringent quality control benchmarks, and tailored bioinformatics pipelines, position the company as a key partner for academic and biopharmaceutical research teams worldwide seeking to unravel the complexities of human disease.
